UK-CAB 67: Friday 23 November 2018

Undetectable equals Untransmittable – What we know now: Friday 23 November 2018

Programme

09.15-09.30
Arrival
Tea and refreshments

09.30-10.00
Welcome and introductions
UK-CAB updates and company pre-meeting

10.00-11.30
Company meeting: ViiV Healthcare

11.30-11.45
Break

11.45-12.45
‘U=U – The Clinician’s Perspective’, Dr Laura Waters

12.45-14.00
Lunch – The Marquis Cornwallis

14.00-14.45
‘U=U – The Community Perspective’, Matthew Hodson

14.45-15:30
‘BHIVA U=U Initiative’, Jo Josh

15.30-15.45
Break

15.45-17.00
‘HIV Glasgow 2018, PRISM Study, BHIVA ART Guidelines’, Roy Trevelion

17.00
Meeting close

Background reading and videos/webcasts

Dolutegravir _ 3TC – Gemini Studies
http://i-base.info/htb/34647

Cabotegravir + rilpivirine long acting inectable treatment
http://www.aidsmap.com/Dual-antiretroviral-regimen-maintains-durable-HIV-suppression-after-switch/page/3117509/

Cabotegravir injections for PrEP – especially the “tail”
http://www.aidsmap.com/The-long-tail-of-injectable-PrEP-is-especially-long-for-women/page/3357646/

Fostemsavir – drug resistant HIV drug
http://i-base.info/htb/35310

ViiV U=U video
The video was recently made by one of the main HIV pharmaceutical companies.
https://www.youtube.com/watch?time_continue=1&v=fI-9vh5QYGM

U=U is also part of an international campaign to raise awareness about this benefit of ART. Currently, more than 720 organisations have joined from over 90 countries.
https://www.preventionaccess.org

Q&A on U=U
Questions and answers about U=U.
http://i-base.info/u-equals-u-qa

The evidence for U=U (Undetectable = Untransmittable): why negligible risk is zero risk
This article reviews key studies over the last twenty years that are the evidence for U=U.
http://i-base.info/htb/32308

Presentations:

Company Presentation by ViiV Healthcare UK (link)

‘U=U – The Clinician’s Perspective’ by Doctor Laura Waters (link)

‘U=U’ – The Community Perspective’ by Matthew Hodson. (link)

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research. For a list of companies that support the UK-CAB please see the “about us” page.

This entry was posted in Background reading, Meetings, News. Bookmark the permalink. Comments are closed, but you can leave a trackback: Trackback URL.